Cover Image

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

Hepatitis B surface antigen, HBsAg seroconversion, Treatment cessation, HBV treatment, Functional cure, Carrier state, Tenofovir EudraCT 2013-004882-15. Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of H...

Full description

Saved in:
Bibliographic Details
Main Authors: Bömmel, Florian van (Author) , Stein, Kerstin (Author) , Heyne, Renate (Author) , Petersen, Jörg (Author) , Buggisch, Peter (Author) , Berg, Christoph Peter (Author) , Zeuzem, Stefan (Author) , Stallmach, Andreas (Author) , Sprinzl, Martin F. (Author) , Schott, Eckart (Author) , Pathil-Warth, Anita (Author) , Arnim, Ulrike von (Author) , Keitel-Anselmino, Verena (Author) , Lohmeyer, Jürgen (Author) , Simon, Karl-Georg (Author) , Trautwein, Christian (Author) , Trein, Andreas (Author) , Hüppe, Dietrich (Author) , Cornberg, Markus (Author) , Lammert, Frank (Author) , Ingiliz, Patrick Philipp (Author) , Zachoval, Reinhart (Author) , Hinrichsen, Holger (Author) , Zipprich, Alexander (Author) , Klinker, Hartmuth (Author) , Schulze zur Wiesch, Julian Constantin Raimar (Author) , Schmiedeknecht, Anett (Author) , Brosteanu, Oana (Author) , Berg, Thomas (Author)
Format: Article (Journal)
Language:English
Published: May 2023
In: Journal of hepatology
Year: 2023, Volume: 78, Issue: 5, Pages: 926-936
ISSN:1600-0641
DOI:10.1016/j.jhep.2022.12.018
Online Access:Resolving-System, kostenfrei: https://doi.org/10.1016/j.jhep.2022.12.018
Resolving-System, kostenfrei: https://doi.org/10.25673/108980
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0168827822034705
Get full text
Author Notes:Florian van Bömmel, Kerstin Stein, Renate Heyne, Jörg Petersen, Peter Buggisch, Christoph Berg, Stefan Zeuzem, Andreas Stallmach, Martin Sprinzl, Eckart Schott, Anita Pathil-Warth, Ulrike von Arnim, Verena Keitel, Jürgen Lohmeyer, Karl-Georg Simon, Christian Trautwein, Andreas Trein, Dietrich Hüppe, Markus Cornberg, Frank Lammert, Patrick Ingiliz, Reinhart Zachoval, Holger Hinrichsen, Alexander Zipprich, Hartmuth Klinker, Julian Schulze zur Wiesch, Anett Schmiedeknecht, Oana Brosteanu, Thomas Berg
Description
Summary:Hepatitis B surface antigen, HBsAg seroconversion, Treatment cessation, HBV treatment, Functional cure, Carrier state, Tenofovir EudraCT 2013-004882-15. Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. Discontinuation of NUC treatment may lead to functional cure; however, to date, the evidence for this has been based on small or non-randomized clinical trials. The STOP-NUC trial was designed with the aim of increasing the HBsAg loss rate using a NUC treatment interruption approach.
Item Description:Online veröffentlicht am 28. März 2023
Gesehen am 05.09.2023
Physical Description:Online Resource
ISSN:1600-0641
DOI:10.1016/j.jhep.2022.12.018

Similar Items